Floatz logo

177lu-dtpa-sc16.56

Neuroendocrine Tumor of the Lung

Memorial Sloan Kettering Cancer CenterradiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Neuroendocrine Tumor of the Lung cohort.

Asset / SponsorPhaseRating
Bms-907351
National Cancer Institute (NCI)
Phase 3B
Ribociclib
M.D. Anderson Cancer Center
Phase 2B
FOSLINANIB
TaiRx, Inc.
Phase 2CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC
Surufatinib
Hutchmed
Phase 2CCC

View all 15 →

Same molecule, other indications

177lu-dtpa-sc16.56 is also rated in:

prostate neuroendocrine neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
neuroendocrine carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →